Cleerly ISCHEMIA vs AVIEW LCS
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if your primary objective is a detailed, non-invasive assessment of coronary artery ischemia at a vessel level using CCTA scans. This tool is specifically designed for precise coronary plaque characterization, stenosis severity assessment, and fractional flow reserve (FFR) estimation to inform personalized heart disease management.
View Cleerly ISCHEMIA →Choose AVIEW LCS if…
Choose AVIEW LCS if you need a comprehensive AI-powered solution for integrated cardiopulmonary assessment, particularly for lung cancer screening and lung nodule management from low-dose CT scans. This tool is ideal for automated lung nodule detection, Lung-RADS classification, emphysema quantification, and includes coronary artery calcification (CAC) scoring from a single scan.
View AVIEW LCS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | AVIEW LCS |
|---|---|---|
| Pricing | Contact for details | Contact for pricing |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers highly flexible deployment options (cloud, hybrid, local, virtualized) and broad integration with standard radiology systems like PACS/RIS, which is crucial for seamless workflow integration in diverse enterprise environments. Its emphasis on automated, comprehensive, and patient-friendly reports, along with 3D visualization, further enhances the overall user experience for both clinicians and patients.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA, a significant advancement in cardiology. It has demonstrated higher diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE) in clinical trials, leading to changes in clinical management and a reduction in the need for further invasive testing.
Pricing & Value
Cleerly ISCHEMIAWhile both tools require direct contact for pricing, Cleerly ISCHEMIA has a distinct advantage with established Category I CPT codes (75580 and 75577) for its services. This provides a clear pathway for reimbursement and integration into existing billing frameworks for healthcare providers, offering a more defined financial value proposition.
Enterprise Readiness
AVIEW LCSAVIEW LCS demonstrates superior enterprise readiness due to its highly flexible deployment options (cloud, hybrid, local, virtualized) and broad integration capabilities with PACS/RIS and other third-party platforms. Its proven deployment in national screening programs across multiple countries further underscores its scalability and robustness for large-scale enterprise use.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA's non-invasive fractional flow reserve (FFR) estimation from CCTA scans is a particularly advanced and impactful application of AI, offering a direct alternative to an invasive procedure for assessing myocardial ischemia. This, coupled with its recognition as 'Best Overall AI Solution' and 'Best Use of AI in Health Tech', highlights its leading innovative edge in cardiac diagnostics.
Support & Docs
AVIEW LCSAVIEW LCS explicitly highlights 'dedicated onboarding support including technical integration, workflow configuration, and user training', indicating a more comprehensive and hands-on approach to customer assistance. While Cleerly provides various resources like publications and FAQs, it does not detail specific, dedicated support services to the same extent.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | AVIEW LCS |
|---|---|---|
| Primary Focus | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | AI-powered solution for the detection and analysis of lung nodules, with integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. |
| Company | Cleerly | Coreline Soft Co. |
| Key Cardiac Analysis | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries | Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) |
| Other Key Analysis | Not specified | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Automated comparison of nodules in follow-up CT scans |
| Reporting | Comprehensive interactive web-based reports | Comprehensive, automated report generation |
| Integration | Integration with PowerScribe via API | Integration with PACS/RIS and third-party platforms |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and AVIEW LCS.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or AVIEW LCS
Backers
Who funded each tool's parent company.